ADHD medication availability and shortage tracker

FDA DRUG SHORTAGES · ASHP · ORANGE BOOK · AS OF OCTOBER 2026

Reviewed by Tariq Halim, MD · Last medical review: November 12, 2026 · Editorial policy

Supply status for every product on this site from three public sources: the FDA Drug Shortages database, ASHP’s drug shortage pages and the FDA Orange Book. Each row shows its own “as of” date and a link to the source. Shortages change weekly, so call your pharmacy before a refill runs out.

How to read this page. FDA and ASHP entries were checked on Oct 20, 2026 (Simtriyo marketing status: Nov 4, 2026; Adderall, Aptensio XR, Daytrana, Quillivant XR, Ritalin LA: all sources rechecked Oct 29, 2026). Orange Book fields are read from the Orange Book data files, October 2026 (products.txt dated Oct 9, 2026). “RX” in the Orange Book means the product is approved and not listed as discontinued; it does not prove that pharmacies have stock. Where sources disagree, both are shown.

For TE codes: generics are listed only when their TE code matches the brand’s (for a discontinued brand, any AB/AA-rated generic of the same form and strength). DEA production quotas are not tracked per product; see background on the 2022–2023 amphetamine shortage.

Background: the 2022–2023 amphetamine shortage

In an Aug 1, 2023 public letter, the FDA and DEA said that amphetamine makers had not used all of the production allowance DEA had given them for 2022, and they asked makers that could not use theirs to give it up so others could make more. Use of nonstimulant ADHD medicines also grew in those years.

FDA–DEA joint letter (signed Califf and Milgram, Aug 1, 2023): for amphetamine medications in 2022, manufacturers sold only about 70% of their allotted quota, and about 1 billion more doses could have been produced but were not made or shipped, with a similar trend in early 2023 data; overall US stimulant dispensing rose 45.5% from 2012 to 2021; manufacturers unable to meet demand were asked to relinquish remaining 2023 quota (DEA and FDA joint letter, accessed Nov 9, 2026). US prescription data 2019–2023: total ADHD medication fills rose 23.8%, from 72,849,441 to 90,183,437; stimulant fills rose 20.4% and nonstimulant fills 60.1%, and stimulant fills fell 6.5% among children (Huskamp 2025; PubMed 40432373). This background does not change any product’s status above.

Where sources disagree (7)

Methylphenidates

Concerta · site status: ER tablet shortage · brand available

FDA Drug Shortages
Methylphenidate ER tablets currently in shortage (first posted Jul 26, 2023); Janssen lists Concerta 18–54 mg Available (reverified Sep 17, 2026); some generic makers limited or unavailable (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Concerta available (updated Oct 14, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 021121, TE AB). 7 ANDA applicant(s) listed RX with a matching TE code: Actavis Laboratories FL Inc (AB), Alkem Laboratories Ltd (AB), Andor Pharmaceuticals LLC (AB), Ascent Pharmaceuticals Inc (AB), Aurolife Pharma LLC (AB), Granules Pharmaceuticals Inc (AB), Osmotica Pharmaceutical US LLC (AB). (October 2026 data file) source (accessdata.fda.gov)

Focalin XR · site status: Partial shortage (ASHP)

FDA Drug Shortages
No dexmethylphenidate entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Brand 5 mg (intermittent) and 35 mg on back order; other brand strengths and several generics available; some generics on back order (updated Oct 15, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 021802, TE AB). 7 ANDA applicant(s) listed RX with a matching TE code: Adare Pharmaceuticals Inc (AB), Ascent Pharmaceuticals Inc (AB), Granules Pharmaceuticals Inc (AB), Impax Laboratories Inc (AB), PH Health Ltd (AB), Platinum Pharmaceuticals (AB), Teva Pharmaceuticals USA (AB). (October 2026 data file) source (accessdata.fda.gov)
Other sources
DailyMed lists 2026 marketing end dates for the Novartis-labeled brand NDCs; Sandoz-labeled NDCs have none (Oct 20, 2026) source (dailymed.nlm.nih.gov)

Jornay PM · site status: Available (ASHP)

FDA Drug Shortages
No methylphenidate ER capsule entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Available, 20–100 mg (updated Oct 14, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 209311). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)

Ritalin LA · site status: Sources differ on brand status

FDA Drug Shortages
No methylphenidate ER capsule entry (checked Oct 29, 2026; checked Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Brand bottles discontinued; Sandoz authorized generic available; Teva LA capsules temporarily unavailable (updated Oct 14, 2026; checked Oct 29, 2026) source (ashp.org)
FDA Orange Book
Brand mixed: 4 strength(s) RX, 1 DISCN (NDA 021284, TE AB1). 2 ANDA applicant(s) listed RX with a matching TE code: Dr Reddys Laboratories SA (AB1), Granules Pharmaceuticals Inc (AB1). The Orange Book notes an FDA determination (Federal Register) that the discontinued brand product strength was not withdrawn for safety or effectiveness reasons. (October 2026 data file) source (accessdata.fda.gov)
Other sources
DailyMed: brand marketing end dates of Sep 30, 2026 (10 and 30 mg) and Oct 31, 2026 (20 and 40 mg) (Oct 29, 2026) source (dailymed.nlm.nih.gov)
Orange Book web search: Ritalin LA 10–40 mg RX/AB1; 60 mg DISCN (Oct 29, 2026) source (accessdata.fda.gov)
Sources disagree
DailyMed lists brand marketing end dates in Sep–Oct 2026 and ASHP lists the brand bottles as discontinued, while the Orange Book still lists four Ritalin LA strengths as RX. Rechecked Oct 29, 2026.

Aptensio XR · site status: Sources differ on brand status

FDA Drug Shortages
No methylphenidate ER capsule entry (checked Oct 29, 2026; checked Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Brand and Rhodes authorized generic on back order (no reason or release estimate given); Teva AB3 generic listed as affected, status not stated (updated Oct 14, 2026; checked Oct 29, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 205831, TE AB3). 1 ANDA applicant(s) listed RX with a matching TE code: Actavis Elizabeth LLC (AB3). (October 2026 data file) source (accessdata.fda.gov)
Other sources
DailyMed: the Aptensio XR label lists marketing end dates of May 20, 2026 for all brand NDCs; it no longer appears in DailyMed search results (Oct 29, 2026) source (dailymed.nlm.nih.gov)
Orange Book web search: Aptensio XR NDA 205831, all seven strengths RX/AB3 (Oct 29, 2026) source (accessdata.fda.gov)
Sources disagree
DailyMed shows brand marketing end dates of May 20, 2026 (and the label no longer appears in DailyMed search) and ASHP lists back orders, while the Orange Book lists all seven Aptensio XR strengths as RX. Rechecked Oct 29, 2026.

Quillivant XR · site status: Available (ASHP)

FDA Drug Shortages
No methylphenidate suspension entry (checked Oct 29, 2026; checked Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Available, all bottle sizes; no generic suspension listed (updated Oct 14, 2026; checked Oct 29, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 202100, TE AB). 1 ANDA applicant(s) listed RX with a matching TE code: Actavis Laboratories FL Inc (AB). (October 2026 data file) source (accessdata.fda.gov)
Other sources
FDA NDC Directory (openFDA data updated Oct 28, 2026) and DailyMed: no product listed under ANDA 206049; only the four Quillivant XR NDCs (Oct 29, 2026) source (accessdata.fda.gov)
Orange Book web search: ANDA 206049 (Actavis Labs FL) RX/AB, approved May 17, 2018 (Oct 29, 2026) source (accessdata.fda.gov)
Sources disagree
The Orange Book lists one AB-rated generic (Actavis, ANDA 206049) as RX, while the FDA NDC Directory and DailyMed list no product under that application and ASHP lists only the brand. Rechecked Oct 29, 2026.

Cotempla XR-ODT · site status: Available (ASHP)

FDA Drug Shortages
No methylphenidate ODT entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Brand (Aytu) and authorized generic (Neos) available (updated Oct 14, 2026) source (ashp.org)
FDA Orange Book
Brand mixed: 3 strength(s) RX, 1 DISCN (NDA 205489, TE AB). 1 ANDA applicant(s) listed RX with a matching TE code: Actavis Elizabeth LLC (AB). (October 2026 data file) source (accessdata.fda.gov)

Azstarys · site status: Marketed

FDA Drug Shortages
No entry for this product (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 212994). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)

Daytrana · site status: Sources differ on brand status

FDA Drug Shortages
Methylphenidate ER film in shortage (first posted Feb 28, 2025); only Noven’s patches distributed by Padagis (authorized-generic NDCs 0574-2410 to -2430) are listed, all four strengths Available; brand Daytrana NDCs are not listed (Noven reverified Oct 16, 2026; checked Oct 29, 2026; checked Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Noven discontinued Daytrana in early 2026; Mylan (Viatris) and Padagis (authorized generic) patches available; bulletin not on the current-shortages list (updated Mar 19, 2026; checked Oct 29, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 021514, TE AB). 1 ANDA applicant(s) listed RX with a matching TE code: Mylan Technologies Inc A Viatris Co (AB). (October 2026 data file) source (accessdata.fda.gov)
Other sources
DailyMed: the Daytrana label (Noven, SPL version 29) lists all four NDCs as marketed with no end date (Oct 29, 2026) source (dailymed.nlm.nih.gov)
DailyMed: Mylan’s generic patch label lists marketing end dates of Jan 31, 2027 (30 mg) and Apr 30, 2027 (10, 15, 20 mg) (Oct 29, 2026) source (dailymed.nlm.nih.gov)
Orange Book web search: Daytrana NDA 021514 RX/AB (all four strengths); Mylan ANDA 206497 RX/AB (Oct 29, 2026) source (accessdata.fda.gov)
Sources disagree
ASHP reports that brand Daytrana was discontinued in early 2026, while the Orange Book lists Daytrana as RX and DailyMed lists all four Daytrana NDCs as marketed with no end date. The FDA shortage entry lists only the Padagis-distributed patches (Available). Rechecked Oct 29, 2026.

Ritalin · site status: Brand available

FDA Drug Shortages
No methylphenidate immediate-release tablet entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Brand Ritalin available; some generics on back order or discontinued (updated Oct 15, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 010187, TE AB). 12 ANDA applicant(s) listed RX with a matching TE code: Abhai LLC (AB), Accord Healthcare Inc (AB), Alkem Laboratories Ltd (AB), Ascent Pharmaceuticals Inc (AB), Bionpharma Inc (AB), Cediprof Inc (AB), Mpp Pharma LLC (AB), Novel Laboratories Inc (AB), Oxford Pharmaceuticals LLC (AB), Prinston Pharmaceutical Inc (AB), SpecGx LLC (AB), Sun Pharmaceutical Industries Inc (AB). (October 2026 data file) source (accessdata.fda.gov)

Adhansia XR · site status: Discontinued

FDA Drug Shortages
No entry for this product (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand DISCN (discontinued) (NDA 212038). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)
Other sources
DailyMed label (revised 06/2021) lists marketing end dates in 2023 (Oct 20, 2026) source (dailymed.nlm.nih.gov)

QuilliChew ER · site status: Available (ASHP)

FDA Drug Shortages
No chewable methylphenidate entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Available, 20–40 mg (updated Oct 14, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 207960). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)

Focalin · site status: Brand marketed · end dates 2027

FDA Drug Shortages
No dexmethylphenidate immediate-release entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 021278, TE AB). 6 ANDA applicant(s) listed RX with a matching TE code: Abhai LLC (AB), Alkem Laboratories Ltd (AB), Cediprof Inc (AB), Novel Laboratories Inc (AB), Sun Pharmaceutical Industries Inc (AB), Tris Pharma Inc (AB). (October 2026 data file) source (accessdata.fda.gov)
Other sources
DailyMed (Sandoz) lists planned marketing end dates in 2027 for all three brand strengths (Oct 20, 2026) source (dailymed.nlm.nih.gov)
Sources disagree
DailyMed lists planned 2027 marketing end dates for brand Focalin; the Orange Book still lists it as RX. These do not conflict yet, but the brand may leave the market in 2027.

Relexxii · site status: Available (FDA listing)

FDA Drug Shortages
Methylphenidate ER tablets in shortage, but Vertical lists Relexxii 18–72 mg Available (reverified Oct 16, 2026; checked Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Relexxii 18–72 mg available (updated Oct 14, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 216117). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)

Metadate CD · site status: Aytu brand discontinued · now lannett

FDA Drug Shortages
No methylphenidate ER capsule entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Aytu-marketed Metadate CD discontinued; Lannett methylphenidate CD capsules available; Amneal on back order (updated Oct 14, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 021259, TE AB2). 3 ANDA applicant(s) listed RX with a matching TE code: Impax Laboratories Inc (AB2), SpecGx LLC (AB2), Teva Pharmaceuticals USA (AB2). (October 2026 data file) source (accessdata.fda.gov)
Other sources
Lannett's Metadate CD label (revised 10/2026) is on DailyMed (Oct 20, 2026) source (dailymed.nlm.nih.gov)
Sources disagree
ASHP lists Metadate CD as discontinued (Aytu), while Lannett now holds the brand with current labeling and the Orange Book lists it as RX. These refer to different companies' products.

Methylin · site status: Marketed (oral solution)

FDA Drug Shortages
No methylphenidate oral solution entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 021419, TE AA). 8 ANDA applicant(s) listed RX with a matching TE code: Abhai LLC (AA), Adaptis Pharma Private Ltd (AA), Alkem Laboratories Ltd (AA), Anda Repository LLC (AA), Ascent Pharmaceuticals Inc (AA), Novel Laboratories Inc (AA), Quagen Pharmaceuticals LLC (AA), Tris Pharma Inc (AA). (October 2026 data file) source (accessdata.fda.gov)
Other sources
Retail stock of the brand liquid not confirmed (Oct 20, 2026)

Methylphenidate ER (10/20 mg) · site status: Ritalin-sr brand discontinued

FDA Drug Shortages
The methylphenidate ER tablet shortage entry lists only 18–72 mg presentations, none at 10 or 20 mg (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
KVK-Tech 10 and 20 mg available; Mallinckrodt (SpecGx) 10 and 20 mg on back order (updated Oct 14, 2026) source (ashp.org)
FDA Orange Book
Brand shown: Ritalin-SR (the reference product). Brand DISCN (discontinued) (NDA 018029). 4 ANDA applicant(s) listed RX: Abhai LLC (AB), Alkem Laboratories Ltd (AB), Granules Pharmaceuticals Inc (AB), SpecGx LLC (AB). The Orange Book notes an FDA determination (Federal Register) that the discontinued brand product was not withdrawn for safety or effectiveness reasons. (October 2026 data file) source (accessdata.fda.gov)

Methylphenidate Chewable · site status: Methylin chewable brand discontinued

FDA Drug Shortages
No methylphenidate chewable entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not covered (the immediate-release bulletin lists no chewable products) (Oct 15, 2026) source (ashp.org)
FDA Orange Book
Brand shown: Methylin chewable tablets (the reference product). Brand DISCN (discontinued) (NDA 021475). 2 ANDA applicant(s) listed RX: Ascent Pharmaceuticals Inc (AB), Rising Pharma Holdings Inc (AB). The Orange Book notes an FDA determination (Federal Register) that the discontinued brand product was not withdrawn for safety or effectiveness reasons. (October 2026 data file) source (accessdata.fda.gov)
Other sources
DailyMed lists generic chewable tablets as marketed by Rising and by labelers of the Ascent product (Oct 20, 2026) source (dailymed.nlm.nih.gov)

Amphetamines

Vyvanse · site status: FDA shortage listed · brand available

FDA Drug Shortages
Lisdexamfetamine capsules and chewable tablets currently in shortage (first posted Jul 14, 2023); Takeda lists Vyvanse capsules 10–70 mg Available (Takeda reverified Oct 15, 2026; checked Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Vyvanse available; Apotex, Hikma, Solco and Sun limited (updated Aug 28, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 021977, TE AB). 18 ANDA applicant(s) listed RX with a matching TE code: Actavis Elizabeth LLC (AB), Alkem Laboratories Ltd (AB), Amneal Pharmaceuticals LLC (AB), Apotex Inc (AB), Ascent Pharmaceuticals Inc (AB), Elite Laboratories Inc (AB), Granules Pharmaceuticals Inc (AB), Hikma Pharmaceuticals USA Inc (AB), Lannett Co Inc (AB), MSN Laboratories Private Ltd (AB), Mylan Pharmaceuticals Inc (AB), Norwich Pharmaceuticals Inc (AB), Prinston Pharmaceutical Inc (AB), Rhodes Pharmaceuticals LP (AB), Sandoz Inc (AB), SpecGx LLC (AB), Sun Pharmaceutical Industries Inc (AB), Teva Pharmaceuticals Development Inc (AB). (October 2026 data file) source (accessdata.fda.gov)
Other sources
FDA chewable-tablet listing (Oct 20, 2026) source (accessdata.fda.gov)

Adderall XR · site status: Brand available (ASHP)

FDA Drug Shortages
No entry for extended-release mixed amphetamine salts capsules (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Brand available in all strengths; several generics on back order or allocation (Teva: increased demand) (updated Sep 29, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 021303, TE AB1). 10 ANDA applicant(s) listed RX with a matching TE code: Actavis Elizabeth LLC (AB1), Ani Pharmaceuticals Inc (AB1), Ascent Pharmaceuticals Inc (AB1), Elite Laboratories Inc (AB1), Granules Pharmaceuticals Inc (AB1), Impax Laboratories Inc (AB1), Lannett Co Inc (AB1), Lupin Inc (AB1), Rhodes Pharmaceuticals LP (AB1), SpecGx LLC (AB1). (October 2026 data file) source (accessdata.fda.gov)

Xelstrym · site status: Supply disruption (noven / ASHP)

FDA Drug Shortages
No Xelstrym entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Dextroamphetamine Transdermal System listed as a current shortage (created Oct 1, 2026; detail page could not be retrieved) (Oct 1, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 215401). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)
Other sources
Noven announced a supply disruption affecting all strengths (active-ingredient shortage) on Jun 1, 2026 (Jun 1, 2026) source (noven.com)

Adderall · site status: Shortage listed · sources differ on brand status

FDA Drug Shortages
Currently in shortage (first posted Oct 12, 2022); Teva lists brand 5, 7.5, 10, 15, 20 and 30 mg Available and 12.5 mg Unavailable (recovery estimated November 2026) (Teva reverified Oct 15, 2026; checked Oct 29, 2026; checked Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Brand 12.5 mg on back order (release estimated November 2026), other brand strengths available; Teva generic 30 mg limited; several generic makers limited or on back order (updated Oct 27, 2026; checked Oct 29, 2026) source (ashp.org)
FDA Orange Book
Brand DISCN (discontinued) (NDA 011522). 18 ANDA applicant(s) listed RX: Actavis Elizabeth LLC (AB), Alkem Laboratories Ltd (AB), Alvogen Inc (AB), Ascent Pharmaceuticals Inc (AB), Aurolife Pharma LLC (AB), Barr Laboratories Inc (AB), Cediprof Inc (AB), Elite Laboratories Inc (AB), Epic Pharma LLC (AB), Granules Pharmaceuticals Inc (AB), Lannett Co Inc (AB), Nuvo Pharmaceutical Inc (AB), Pharmobedient Consulting LLC (AB), Rhodes Pharmaceuticals LP (AB), Sandoz Inc (AB), SpecGx LLC (AB), Sun Pharmaceutical Industries Inc (AB), Zydus Pharmaceuticals USA Inc (AB). The Orange Book notes an FDA determination (Federal Register) that the discontinued brand product was not withdrawn for safety or effectiveness reasons. (October 2026 data file) source (accessdata.fda.gov)
Other sources
DailyMed: Teva’s Adderall label names ANDA 040422 and lists all seven NDCs as marketed with no end date (Oct 29, 2026) source (dailymed.nlm.nih.gov)
Orange Book web search: NDA 011522 (Adderall) DISCN; ANDA 040422 (Barr Laboratories) RX/AB (Oct 29, 2026) source (accessdata.fda.gov)
Sources disagree
The Orange Book lists the original brand Adderall application (NDA 011522) as discontinued, while DailyMed lists Teva’s Adderall as marketed under ANDA 040422 (RX in the Orange Book) and the FDA and ASHP shortage pages list most brand strengths as available. Rechecked Oct 29, 2026.

Mydayis · site status: Brand available (ASHP)

FDA Drug Shortages
No entry for this product (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Brand available in all strengths (updated Sep 29, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 022063, TE AB2). 3 ANDA applicant(s) listed RX with a matching TE code: SpecGx LLC (AB2), Sun Pharmaceutical Industries Inc (AB2), Teva Pharmaceuticals USA Inc (AB2). (October 2026 data file) source (accessdata.fda.gov)

Adzenys XR-ODT · site status: Available (ASHP)

FDA Drug Shortages
No entry for this product (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Brand (Aytu) and authorized generic (Neos) available (updated Sep 29, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 204326, TE AB). 1 ANDA applicant(s) listed RX with a matching TE code: Actavis Laboratories FL Inc (AB). (October 2026 data file) source (accessdata.fda.gov)

Dyanavel XR · site status: Available (ASHP)

FDA Drug Shortages
No entry for this product (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Tablets and suspension available (updated Sep 29, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 208147). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)

Evekeo · site status: Marketed

FDA Drug Shortages
No amphetamine sulfate tablet entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (ANDA 200166, TE AA). 9 ANDA applicant(s) listed RX with a matching TE code: Alkem Laboratories Ltd (AA), Amneal Pharmaceuticals Of New York LLC (AA), Aurolife Pharma LLC (AA), Bionpharma Inc (AA), Epic Pharma LLC (AA), Granules Pharmaceuticals Inc (AA), Pharmazone (AA), Prinston Pharmaceutical Inc (AA), SpecGx LLC (AA). (October 2026 data file) source (accessdata.fda.gov)

Arynta · site status: Marketed (spl 03/2026)

FDA Drug Shortages
No Arynta-specific entry (the lisdexamfetamine entries cover capsules and chewable tablets) (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 219847). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)
Other sources
DailyMed lists a marketing start date of Mar 20, 2026 (Oct 20, 2026) source (dailymed.nlm.nih.gov)

Zenzedi · site status: Marketed

FDA Drug Shortages
No dextroamphetamine immediate-release tablet entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Zenzedi is not listed under its brand name; shown: Azurity's dextroamphetamine sulfate tablets (ANDA). Brand RX (active) (ANDA 090533, TE AA). 7 ANDA applicant(s) listed RX with a matching TE code: Aurolife Pharma LLC (AA), Avanthi Inc (AA), Barr Laboratories Inc (AA), Novel Laboratories Inc (AA), Nuvo Pharmaceutical Inc (AA), SpecGx LLC (AA), Winder Laboratoiries LLC (AA). (October 2026 data file) source (accessdata.fda.gov)

ProCentra · site status: Marketed

FDA Drug Shortages
No dextroamphetamine oral solution entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
ProCentra is not listed under its brand name; shown: Prasco's dextroamphetamine sulfate oral solution (ANDA). Brand RX (active) (ANDA 040776, TE AA). 1 ANDA applicant(s) listed RX with a matching TE code: Tris Pharma Inc (AA). (October 2026 data file) source (accessdata.fda.gov)

Dexedrine Spansule · site status: Brand available (ASHP)

FDA Drug Shortages
No dextroamphetamine ER capsule entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Dexedrine 10 mg available; a Teva generic on back order (release estimated late November 2026) (updated Aug 19, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 017078, TE AB). 2 ANDA applicant(s) listed RX with a matching TE code: Actavis Elizabeth LLC (AB), SpecGx LLC (AB). (October 2026 data file) source (accessdata.fda.gov)

Evekeo ODT · site status: Discontinued

FDA Drug Shortages
No entry for this product (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand DISCN (discontinued) (NDA 209905). No ANDA generic listed as RX for the same form and strengths. The Orange Book notes an FDA determination (Federal Register) that the discontinued brand product was not withdrawn for safety or effectiveness reasons. (October 2026 data file) source (accessdata.fda.gov)
Other sources
No current DailyMed label is listed (Oct 20, 2026)

Desoxyn · site status: Listed rx (orange book)

FDA Drug Shortages
No methamphetamine entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 005378, TE AA). 2 ANDA applicant(s) listed RX with a matching TE code: Dr Reddys Laboratories SA (AA), Hikma Pharmaceuticals USA Inc (AA). (October 2026 data file) source (accessdata.fda.gov)
Other sources
Wholesaler and pharmacy stock not confirmed (Oct 20, 2026)

Nonstimulants

Qelbree · site status: Marketed

FDA Drug Shortages
No viloxazine entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 211964). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)

Strattera (atomoxetine) · site status: Brand discontinued

FDA Drug Shortages
No atomoxetine entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand DISCN (discontinued) (NDA 021411). 9 ANDA applicant(s) listed RX: Apotex Inc (AB), Aurobindo Pharma Ltd (AB), Dr Reddys Laboratories Ltd (AB), Glenmark Pharmaceuticals Ltd (AB), Hetero Labs Ltd Unit V (AB), Pharmazone (AB), Strides Pharma Global Pte Ltd (AB), Teva Pharmaceuticals USA (AB), Zydus Pharmaceuticals USA Inc (AB). The Orange Book notes an FDA determination (Federal Register) that the discontinued brand product was not withdrawn for safety or effectiveness reasons. (October 2026 data file) source (accessdata.fda.gov)

Intuniv · site status:

FDA Drug Shortages
Guanfacine ER appears only as a discontinuation (Actavis, 1–4 mg, posted Nov 13, 2025) (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 022037, TE AB). 10 ANDA applicant(s) listed RX with a matching TE code: Actavis Elizabeth LLC (AB), Alembic Pharmaceuticals Ltd (AB), Apotex Inc (AB), Fosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd (AB), Rubicon Research Ltd (AB), Sandoz Inc (AB), Teva Pharmaceuticals USA (AB), Twi Pharmaceuticals Inc (AB), Unichem Laboratories Ltd (AB), Yichang Humanwell Pharmaceutical Co Ltd (AB). (October 2026 data file) source (accessdata.fda.gov)

Kapvay · site status: Brand discontinued

FDA Drug Shortages
No clonidine ER tablet entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand DISCN (discontinued) (NDA 022331). 7 ANDA applicant(s) listed RX: Actavis Elizabeth LLC (AB1), Ajanta Pharma Ltd (AB1), Chartwell Rx Sciences LLC (AB1), Jubilant Generics Ltd (AB1), Novast Laboratories Ltd (AB1), Somerset Therapeutics LLC (AB1), Xiamen LP Pharmacuetical Co Ltd (AB1). The Orange Book notes an FDA determination (Federal Register) that the discontinued brand product was not withdrawn for safety or effectiveness reasons. (October 2026 data file) source (accessdata.fda.gov)

Onyda XR · site status: Marketed

FDA Drug Shortages
No clonidine entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 217645). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)

Atoncy · site status: Marketed (dailymed spl)

FDA Drug Shortages
No atomoxetine entry (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
Not on the current shortage list (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Brand RX (active) (NDA 220320). No ANDA generic listed as RX for the same form and strengths. (October 2026 data file) source (accessdata.fda.gov)
Other sources
DailyMed lists Atoncy and an authorized generic of the solution as marketed (start Mar 20, 2026) (Oct 20, 2026) source (dailymed.nlm.nih.gov)

Newer mechanism (centanafadine)

Simtriyo · site status: Now marketable · check pharmacy availability

FDA Drug Shortages
No centanafadine entry when checked (before marketing); not rechecked since (as of Oct 20, 2026) source (accessdata.fda.gov)
ASHP
No centanafadine entry when checked (before marketing); not rechecked since (as of Oct 20, 2026) source (ashp.org)
FDA Orange Book
Not listed in the October 2026 Orange Book data file (FDA approval became effective Oct 30, 2026, when DEA placed centanafadine in Schedule III; not rechecked since). (October 2026 data file) source (accessdata.fda.gov)
Other sources
Now marketable: DEA placed centanafadine in Schedule III by an interim final rule published and effective Oct 30, 2026 (91 FR 68470), which made the FDA approval effective. No launch press release found and pharmacy stocking not confirmed; check pharmacy availability (Nov 4, 2026) source (federalregister.gov)
DailyMed SPL version 1 (published Oct 26, 2026) lists a marketing start date of Oct 24, 2026 (Nov 4, 2026) source (dailymed.nlm.nih.gov)

Sources

  • U.S. Food and Drug Administration. FDA Drug Shortages database. accessdata.fda.gov (checked Oct 20, 2026).
  • American Society of Health-System Pharmacists. Current drug shortages. ashp.org (bulletin dates on each row; list checked Oct 20, 2026).
  • U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), data files, October 2026. accessdata.fda.gov.
  • DailyMed (National Library of Medicine) product labels, linked on each row.
  • Machine-readable copy of this table: availability.json.
EDUCATIONAL INFORMATION ONLY. Not medical advice. Medication decisions require individualized assessment by a qualified clinician. Do not start, stop, switch or change the dose of a medication without your prescriber. See the medical disclaimer.
Back to top